Drugs removed from national reimbursement drug list vs Cardiometabolic RNA and next-generation lipid drug trial starts in China
In 2025, drugs removed from national reimbursement drug list in China stood at 29, against 12 for cardiometabolic RNA and next-generation lipid drug trial starts.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Drugs removed from national reimbursement drug list and Cardiometabolic RNA and next-generation lipid drug trial starts
Unit: count · 8 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Drugs removed from national reimbursement drug list | 2025 | Actual | 29 |
| Drugs removed from national reimbursement drug list | 2024 | Actual | 43 |
| Cardiometabolic RNA and next-generation lipid drug trial starts | 2025 | Actual | 12 |
| Cardiometabolic RNA and next-generation lipid drug trial starts | 2024 | Actual | 12 |
| Cardiometabolic RNA and next-generation lipid drug trial starts | 2023 | Actual | 7 |
| Cardiometabolic RNA and next-generation lipid drug trial starts | 2022 | Actual | 3 |
| Cardiometabolic RNA and next-generation lipid drug trial starts | 2021 | Actual | 4 |
| Cardiometabolic RNA and next-generation lipid drug trial starts | 2020 | Actual | 0 |
Shared periods
Side by side
2 periods are published for both series in China as annual figures on the same basis. Comparing anything else would mean comparing different periods.
Provenance
Where these numbers come from
Drugs removed from national reimbursement drug list
Count of drugs excluded or delisted from a national reimbursement drug list during a catalog adjustment cycle.
2 observations charted in China · source organisations: State Council, NHSA
Cardiometabolic RNA and next-generation lipid drug trial starts
Count of interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in China · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring